Precision Medicine in Oncology

The FDA has granted full approval to lorlatinib, expanding its indication to include frontline treatment for patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC.

ACCC president Randall Oyer, MD, gives insight into the ongoing collaboration between the ACCC and ASCO to foster minority participation in cancer clinical trials.

Excitement around gene therapy is back and greater than before. Although safety remains a concern, investigators are breaking ground in cell and gene therapy, and many believe that ultimately, a string of cancer cures will follow.

Tepmetko (tepotinib) was FDA approved for the treatment of adult patients with metastatic non-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

A report published by the Personalized Medicine Coalition shows that the number of personalized medicines on the market grew at the highest rate ever recorded by the organization from 2016-2020.

During the panel on precision medicine at the Quality Cancer Care Alliance (QCCA) Fall Leadership Summit, the speakers discussed testing every patient upfront with a broad molecular assessment and bringing clinical research to the patient.

A top-5 roundup of some of 2020's advancements in the precision oncology space.

A report published by the Personalized Medicine Coalition (PMC) shows that the number of personalized medicines on the market is growing at the highest rate ever recorded by the organization.

Managing the constantly evolving selection of therapies in oncology can be difficult, but is of the utmost importance to get the right treatment to the right patient, agreed a panel at Patient-Centered Oncology Care® 2020.

A new study validates the application of duplex sequencing in detecting mutations caused by chemical carcinogens.

According to the final panel at Patient-Centered Oncology Care®, clinical pathways can create a new problem: if each payer tries to impose its own pathways, it’s an administrative and ethical nightmare.

The Caris Precision Oncology Alliance has brought together academic institutions and community practices with the goal of performing research and exchanging evidence and ideas for new types of tests, said W. Michael Korn, MD.

The findings help explain why costly CAR T-cell therapy does not work for some patients.

Data presented at the 62nd Annual ASH Meeting demonstrated the clinical utility of Adaptive Biotechnologies’ clonoSEQ next-generation sequencing to detect MRD in multiple myeloma patients.

An oncolytic virus called CF33 developed at City of Hope shows potential for colon cancer treatment and tumor regrowth immunity in mouse models.

Penn Medicine researchers use mice experiments to find a potential solution to the challenge of delivering CAR T cell treatments to solid tumors in glioblastoma.

There are certain diseases, like lung cancer, that are leading the way in precision medicine and where broad molecular testing is recommended, said W. Michael Korn, MD, of University of California, San Francisco, and Caris Life Sciences.

In the past, there was a greater discrepancy in access to precision oncology testing, which has closed somewhat; however, there are some disenfranchised populations who still struggle to access this care.

A first-of-its-kind partnership between OneOncology and Genentech aims to bring more personalized cancer care to community oncology centers nationwide.

Results of the artificial intelligence (AI) model were consistent no matter which immune checkpoint inhibitor (ICI) therapy patients received, suggesting that some biomarkers are not necessarily specific to the checkpoint target.

A precision oncology tumor board at City of Hope identified colorectal cancer patients with possible hereditary predisposition who were not referred for cancer genetics evaluation previously.

In a pair of sessions at the Quality Cancer Care Alliance Virtual Fall Leadership Summit, speakers discussed the promise of precision medicine for not only informing individuals’ cancer treatment decisions but also identifying individuals at high risk before disease develops.

The liquid serum assay was cleared for use as a companion diagnostic for olaparib to identify patients with BRCA1/2- and/or ATM-mutated metastatic castration-resistant prostate cancer.

Understanding these genetic variants discovered through sequencing efforts is key to further progress in clinical genetics.

The Quality Cancer Care Alliance is focusing on 2 major topics: value-based care and innovation, and precision oncology is the intersection of those 2 issues, said Sibel Blau, MD.